Akili Interactive is a digital medicine company that develops video-game-based therapeutics designed to treat cognitive impairments. Its flagship product, EndeavorRx, is an FDA-cleared, doctor-prescribed video game treatment for children with ADHD, cleared by the FDA in June 2020 as the first prescription treatment delivered through a video game. Founded in 2011 and based in Boston, Massachusetts, Akili was incubated by PureTech Health. The company went public on the Nasdaq via a SPAC merger with Social Capital Suvretta Holdings Corp. I in August 2022 under the ticker AKLI, and was subsequently taken private through an acquisition by Virtual Therapeutics in July 2024.
Akili has been acquired
This company is no longer available on our private secondary market.
Company data and valuation marks are estimates and may be incomplete, stale, erroneous, or revised.
Founded
2011
Employees
51–200
Total Funding
$270.6M
6 rounds
Matt Franklin became President and CEO of Akili effective October 5, 2023, with co-founder Eddie Martucci moving to Board chair.
Funding data and valuation marks are estimates and may be incomplete, stale, erroneous, or revised.
Total raised $270.6M across 6 rounds
Last updated 09-19-2026
| Date | Round | Amount Raised | Valuation | Lead Investors |
|---|---|---|---|---|
| May 26, 2021 | Series D | $110M | $0.32B *estimated | Neuberger Berman |
| May 26, 2021 | Venture debt (SVB) | $50M | — | Silicon Valley Bank |
| Aug 9, 2018 | Series C Extension | $13.2M | — | Not disclosed |
Matt Franklin
Chief Executive Officer
Access live market data
Sign UpData collected with AI, which can make mistakes. Please double-check this information.